Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atebimetinib + mGnP vs GnP in metastatic pancreatic adenocarcinoma
NCT07562152Phase 3Recruiting
- Sponsor
- Immuneering Corporation
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of atebimetinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Immuneering Corporation. Started Jun 2026; status: recruiting.
02
Drugs
atebimetinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07562152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562152.